The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease

CCL2 Cytokine Serves as Biomarker in Interstitial Lung Disease

December 18, 2017 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF
A 3D illustration of cytokines.

A 3D illustration of cytokines.
sciencepics / SHUTTERSTOCK.COM

A recent prospective, observational cohort study of potential clinical biomarkers for progression to interstitial lung disease (ILD) in patients with early systemic sclerosis (SSc) found that higher levels of CCL2 circulating in their plasma predicted both faster ILD progression and poorer survival rates than in those with lower levels.1

You Might Also Like
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
Explore This Issue
December 2017

CCL2, also known as monocyte chemo­attractant protein-1, is a small cytokine belonging to the CC chemokine family. Cytokines are substances, such as interferon, interleukin and growth factors, secreted by cells in the immune system that have immunologic effects on other cells. Cytokines can be either pro-inflammatory or anti-inflammatory, and can be further subdivided into Th1-type and Th2-type cytokines.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

The new study’s results combine two independent cohorts of patients with early SSc in Texas and Canada to examine the predictive significance of cytokines and chemokines for long-term progression of SSc-related ILD, says lead author Minghua Wu, MD, of the University of Texas Health Sciences Center in Houston. She and colleagues in Texas measured plasma levels obtained at baseline for 11 key cytokines using a highly sensitive multiplex sandwich immunoassay.

The Genetics vs. Environment in Scleroderma Outcome Study (GENISOS) in Texas tested a total of 266 patients with early SSc, along with 97 matched healthy controls. The companion replication cohort study by the Canadian Scleroderma Research Group looked for several of the same cytokines, including CCL2, in serum samples of 171 patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Researchers adjusted for age, sex and ethnicity, and the results remained independent of other biomarkers. The most significant finding indicated higher levels of CCL2 predicted faster decline in forced vital capacity (FVC), a measure of lung function that served as a surrogate for the severity of SSc-related ILD. Researchers tested FVC at patients’ initial visit and annually thereafter, with a mean follow-up from 4.36–5.72 years.

Among the 11 cytokines under examination by the Texas group, the data showed IL-10 was a significant predictor of ILD progression as well, but in the opposite direction: Higher IL-10 levels in the plasma meant slower progression. The Canadian data did not repeat this IL-10 finding.

Higher levels of CCL2 … predicted faster decline in forced vital capacity (FVC), a measure of lung function.

A New Therapeutic Target?

SSc, an autoimmune fibrotic disease that presents a distinct cytokine profile, is associated with high mortality, with few treatment options and no single Food and Drug Administration-approved medication for SSc-related ILD, says Dr. Wu’s UT colleague, Shervin Assassi, MD. “ILD, along with other pulmonary involvement, is the primary cause of mortality in this population,” he says. “The course of ILD is highly variable. The few existing clinical predictors of progression [we have] have not [proved] sufficient.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: ACR Journal Review, American College of Rheumatology, Biomarker, chemokine, Clinical, cytokine, early systemic sclerosis, forced vital capacity, ILD, Interstitial Lung Disease, lung function, outcome, patient care, Research, Rheumatic Disease, rheumatology, studyIssue: December 2017

You Might Also Like:
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • MUC5B Promoter Variant Associated with RA with Interstitial Lung Disease
  • What Rheumatologists Need to Know about Diagnosing and Managing Interstitial Lung Disease (ILD)

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)